High prevalence of coinfection of azithromycin-resistant with other STIs: a prospective observational study of London-based symptomatic and STI-contact clinic attendees.

Objectives: Azithromycin treatment of (CT) may not be adequate to treat concomitant (MG) infection, and particularly if MG has macrolide resistance-associated mutations (MG-MRAMs). We estimated prevalence of coinfections of CT with MG carrying MRAM, and risk factors for MG-MRAM among a sexual health clinic population.

Study Design And Setting: Among symptomatic and STI-contact clinic attendees in London, prevalence of CT-MG coinfection and MG-MRAM were estimated using nucleic acid amplification testing and Sanger sequencing, respectively, and their associated risk factors analysed using logistic regression.

Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital infection.

Background: Mass drug administration (MDA) of 20 mg/kg (maximum 1 g in adults) azithromycin for ocular (CT) infection is a key component of the WHO trachoma elimination strategy. However, this dose may be suboptimal in infection and may encourage emergence of antimicrobial resistance (AMR) to azithromycin.

Objectives: To determine the effect of MDA for trachoma elimination on prevalence, strain type and azithromycin resistance.